Table 1.
Clinical characteristics of the five examined patients.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Sex | F | M | M | M | M |
| Age (years) | 66 | 65 | 52 | 66 | 63 |
| Histological classification | ad | ad | ad | ad | ad |
| Clinical stage at diagnosis | IIIA | IIA | IIB | I | IIIB |
| EGFR mutation category | Exon 19 del | Exon 19 del | Exon 19 del | Exon 21 L858R | Exon 18 D719C |
| Tissue collection site (at diagnosis) | Lung | Lung | Lung | Lung | Lung |
| Method of tissue collection (at diagnosis) | Surgery | Surgery | Surgery | Surgery | Surgery |
| Tissue collection site (second biopsy) | Lung | Lung | Lung | Bone | Lymph node |
| Method of tissue collection (second biopsy) | Surgery | Surgery | Surgery | CT | Surgery |
| Presence of T790M mutation (second biopsy) | Yes | Yes | Yes | No | No |
| EGFR-TKI used before the second biopsy | Gefitinib | Gefitinib | Erlotinib | Afatinib | Afatinib |
| EGFR-TKI used after the second biopsy | Osimertinib | Osimertinib | Osimertinib | None | None |
F: female, M: male, ad: adenocarcinoma, EGFR: epidermal growth factor receptor, del: deletion, CT: CT-guided biopsy, TKI: tyrosine kinase inhibitor.